Literature DB >> 15808492

Synthesis and evaluation of potential inhibitors of eIF4E cap binding to 7-methyl GTP.

Phalguni Ghosh1, Chunkyung Park, Mark S Peterson, Peter B Bitterman, Vitaly A Polunovsky, Carston R Wagner.   

Abstract

Cap-dependent translation is initiated by the binding of eIF4E to capped mRNA (m(7)GpppN). We have prepared a small library of 7-methyl guanosine nucleoside and nucleotide analogs and evaluated their ability to inhibit eIF4E binding to 7-methyl GTP with a competitive eIF4E binding immunoassay. 5'-H-Phosphonate derivatives in which the 2'- and 3'-riboside hydroxyls were tethered together by an isopropylidene group were shown to be a new class of inhibitors of eIF4E binding to capped mRNA.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15808492     DOI： 10.1016/j.bmcl.2005.01.080

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN： 0960-894X            Impact factor:   2.823


  15 in total

1.  Synthesis of N²-modified 7-methylguanosine 5'-monophosphates as nematode translation inhibitors.

Authors:  Karolina Piecyk; Richard E Davis; Marzena Jankowska-Anyszka
Journal:  Bioorg Med Chem       Date:  2012-06-10       Impact factor: 3.641

2.  Synthesis of 7-benzylguanosine cap-analogue conjugates for eIF4E targeted degradation.

Authors:  Tanpreet Kaur; Arya Menon; Amanda L Garner
Journal:  Eur J Med Chem       Date:  2019-01-31       Impact factor: 6.514

3.  Discovery of Lysine-Targeted eIF4E Inhibitors through Covalent Docking.

Authors:  Xiaobo Wan; Tangpo Yang; Adolfo Cuesta; Xiaming Pang; Trent E Balius; John J Irwin; Brian K Shoichet; Jack Taunton
Journal:  J Am Chem Soc       Date:  2020-03-04       Impact factor: 15.419

4.  Resistance to EGFR-TKI can be mediated through multiple signaling pathways converging upon cap-dependent translation in EGFR-wild type NSCLC.

Authors:  Manish R Patel; Joe Jay-Dixon; Ahad A Sadiq; Blake A Jacobson; Robert A Kratzke
Journal:  J Thorac Oncol       Date:  2013-09       Impact factor: 15.609

5.  Nontoxic chemical interdiction of the epithelial-to-mesenchymal transition by targeting cap-dependent translation.

Authors:  Brahma Ghosh; Alexey O Benyumov; Phalguni Ghosh; Yan Jia; Svetlana Avdulov; Peter S Dahlberg; Mark Peterson; Karen Smith; Vitaly A Polunovsky; Peter B Bitterman; Carston R Wagner
Journal:  ACS Chem Biol       Date:  2009-05-15       Impact factor: 5.100

6.  Treatment of breast and lung cancer cells with a N-7 benzyl guanosine monophosphate tryptamine phosphoramidate pronucleotide (4Ei-1) results in chemosensitization to gemcitabine and induced eIF4E proteasomal degradation.

Authors:  Shui Li; Yan Jia; Blake Jacobson; Joel McCauley; Robert Kratzke; Peter B Bitterman; Carston R Wagner
Journal:  Mol Pharm       Date:  2013-02-04       Impact factor: 4.939

7.  Antisense oligonucleotide targeting eukaryotic translation initiation factor 4E reduces growth and enhances chemosensitivity of non-small-cell lung cancer cells.

Authors:  S C Thumma; B A Jacobson; M R Patel; B W Konicek; M J Franklin; J Jay-Dixon; A Sadiq; A De; J R Graff; R A Kratzke
Journal:  Cancer Gene Ther       Date:  2015-07-31       Impact factor: 5.987

8.  Eukaryotic initiation factor 4E binding protein family of proteins: sentinels at a translational control checkpoint in lung tumor defense.

Authors:  Yong Y Kim; Linda Von Weymarn; Ola Larsson; Danhua Fan; Jon M Underwood; Mark S Peterson; Stephen S Hecht; Vitaly A Polunovsky; Peter B Bitterman
Journal:  Cancer Res       Date:  2009-10-20       Impact factor: 12.701

9.  Expression, purification and characterization of recombinant mouse translation initiation factor eIF4E as a dihydrofolate reductase (DHFR) fusion protein.

Authors:  Phalguni Ghosh; Jilin Cheng; Tsui-Fen Chou; Yan Jia; Svetlana Avdulov; Peter B Bitterman; Vitaly A Polunovsky; Carston R Wagner
Journal:  Protein Expr Purif       Date:  2008-03-31       Impact factor: 1.650

10.  Design, synthesis and evaluation of analogs of initiation factor 4E (eIF4E) cap-binding antagonist Bn7-GMP.

Authors:  Yan Jia; Ting-Lan Chiu; Elizabeth A Amin; Vitaly Polunovsky; Peter B Bitterman; Carston R Wagner
Journal:  Eur J Med Chem       Date:  2009-12-06       Impact factor: 6.514
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.